Aclarion, Inc. (NASDAQ: ACON) has seen recent insider activity following a filing with the Securities and Exchange Commission. Scott Breidbart, who serves as a director for the company, executed a purchase of 5,664 shares of common stock on May 12, 2026. The total value of this transaction was $18,011, with the acquisition price set at $3.18 per share.
This specific purchase was made on the public market at a price slightly above the current trading level of $3.15. As a result of this move, Mr. Breidbart now maintains a direct holding of 5,664 shares of Aclarion common stock. This insider buying comes against a backdrop where the company's stock has seen a decline of 54% over the last six months, though recent data indicates the stock has provided strong returns during the most recent three-month period despite general weakness.
Operational and Clinical Milestones
Beyond the insider transaction, Aclarion has reported significant growth in its core platform metrics. For the first quarter of 2026, the company documented a 196% year-over-year surge in scan volumes for its Nociscan platform. Management attributes this substantial increase to both the activation of new accounts and heightened utilization rates at existing sites.
In tandem with operational growth, the company is advancing its clinical research initiatives. Aclarion has expanded its CLARITY trial, which is designed to evaluate Nociscan in patients suffering from discogenic low back pain, by adding Lanman Spinal Neurosurgery as a new clinical site. Furthermore, a new trial agreement has been established with Weill Cornell Medicine to study the long-term impacts of lumbar microdiscectomy surgery.
Technological advancements also continue to progress for the firm. Aclarion recently announced the issuance of a U.S. patent for its artificial intelligence-based platform. This technology is intended to assist in the identification of sources of chronic low back pain. The patent specifically covers machine learning models that are designed to improve the efficiency of the Nociscan platform when analyzing data from magnetic resonance spectroscopy.
Capital Allocation and Financial Strategy
Aclarion has also moved to implement a formal capital return strategy. The company has authorized a share repurchase program totaling $2.5 million, which is intended to be executed over a 12-month period.